Houston Optivision is categorized under Commercial Medical Research in Houston, TX and active since 1983.
Houston Optivision was established in 1983, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Sami G El Hage at the company’s single location by writing to 5320 Richmond Avenue, Houston, Texas TX 77056 or by phoning (713) 621-9004. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Houston Optivision |
| Contact Person: | Sami G El Hage |
| Address: | 5320 Richmond Avenue, Houston, Texas 77056 |
| Phone Number: | (713) 621-9004 |
| Website Address: | optivision10.com |
| Annual Revenue (USD): | $2.500.000 to $4.999.999 |
| Founded: | 1983 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Houston Optivision was started in 1983 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.
Feel free to contact Sami G El Hage for inquiries that concern Houston Optivision by calling the company number (713) 621-9004, as your correspondence is most welcome. Additionally, the physical location of the single location of Houston Optivision can be found at the coordinates 29.731747,-95.470863 as well as the street address 5320 Richmond Avenue in Houston, Texas 77056.
For its online presence, you may visit Houston Optivision’s website at optivision10.com and engage with its social media outlets through on Twitter and on Facebook.